Catalog No.
Product Name
Application
Product Information
Citations
-
CB1 Ligand
GAT228 is an allosteric ligand for cannabinoid receptor 1 (CB1). This compound modulates CB1 receptor activity, influencing cannabinoid signaling pathways. GAT228 is employed in research focused on cannabinoid system mechanisms, neuropharmacology, and potential therapeutic applications in pain management and metabolic disorders. -
CB1/2 Agonist
AB-FUBICA is a potent agonist for CB1 and CB2 receptors, serving as a valuable tool in cannabinoid research. It functions by activating G-protein coupled inwardly rectifying potassium channels (GIRK) through its binding to these receptors, demonstrating significant cannabinoid-like activity. With EC50 values of 21 nM for CB1 and 15 nM for CB2, AB-FUBICA is ideal for investigating pain management, neurodegenerative diseases, and inflammation-related pathways. -
Cannabinoid
FDU-PB-22 is a synthetic cannabinoid that primarily targets cannabinoid receptors. It is rapidly metabolized in human liver microsomes, exhibiting a half-life of 12.4 minutes. This compound is valuable for research applications involving cannabinoid receptor signaling and pharmacokinetics, enabling investigations into the effects of synthetic cannabinoids on physiological and neurological processes. -
CB1/CB2 Ligand
9β,10β-epoxy Hexahydrocannabinol is a selective ligand for the cannabinoid receptors CB1 and CB2, exhibiting binding affinities of 224 nM and 335 nM, respectively. This compound has demonstrated significant biological activities, including the reduction of locomotor activity, induction of catalepsy, and lowering of body temperature, along with antinociceptive effects in murine models. Its relevant pharmacological profile makes it a valuable tool for research focused on the mechanisms underlying nervous system diseases. -
Endocannabinoid Analog
AM11638 is an endocannabinoid analog that selectively targets cannabinoid receptors CB1 and CB2, demonstrating notable analgesic properties. This compound is valuable for investigating various neurological disorders and inflammation-related conditions, providing a platform for the development of therapeutic interventions in these areas. -
Multi-target modulator
PQM-244 is a multi-target modulator that primarily interacts with TRPV1 and cannabinoid receptors CB1 and CB2. It exhibits noteworthy peripheral antinociceptive properties, effectively addressing both neurogenic and inflammatory pain. Additionally, PQM-244 demonstrates antioxidant activity with an IC50 of 14.15 µM for radical scavenging of DPPH. This compound is suitable for research applications related to chronic pain and inflammatory conditions, including diabetes, atherosclerosis, and Alzheimer's disease. -
CB2 Inverse-Agonist
COR170 is a selective inverse agonist of the CB2 receptor, identified as a 4-quinolone-3-carboxylic acid derivative with a Ki value of 3.8 nM. This compound has shown potential in modulating inflammatory responses and provides insights into neuroprotective mechanisms. It is valuable for research applications focused on understanding the role of CB2 receptors in various biological processes related to inflammation and neuroprotection. -
CB1 Inhibitor
CB1-IN-2 is a selective CB1 receptor inhibitor, characterized by an IC50 of 0.644 μM. This compound effectively penetrates the blood-brain barrier, making it suitable for studies exploring its potential central nervous system effects. CB1-IN-2 can be applied in research focused on cannabinoid receptor modulation and its implications in various neurological and psychological conditions. -
Cannabinoid Receptor Ligand
Pirnabine is a cannabinoid receptor ligand that selectively interacts with the CB1 and CB2 receptors. This compound has demonstrated potential in modulating intraocular pressure, making it relevant for glaucoma research. Investigating Pirnabine may provide insights into cannabinoid therapeutic strategies for ocular conditions. -
Cannabinoid
AB-FUBINACA 3-fluorobenzyl isomer is a synthetic cannabinoid that selectively targets CB1 receptors in the central nervous system, demonstrating a binding affinity of Ki= 0.9 nM. This compound exhibits significant anticonvulsant activity, making it valuable for research related to epilepsy and other neurological disorders. Its role in modulating cannabinoid receptor activity offers potential insights into endocannabinoid system functions and therapeutic applications. -
CB1 Receptor Ligand
Prostaglandin E2-1-glyceryl ester serves as a selective ligand for the CB1 receptor, functioning as an important endocannabinoid modulator. This compound is known to induce a rapid and transient increase in intracellular free calcium concentrations, thus playing a vital role in signal transduction pathways. Its functionality makes it a valuable reagent for research investigating cannabinoid receptor dynamics and related physiological effects. -
CB1 Agonist
AM8936 is a potent and balanced agonist of the cannabinoid receptor type-1 (CB1), exhibiting EC50 values of 8.6 nM for rat CB1 (rCB1) and 1.4 nM for human CB1 (hCB1). With a high affinity for rCB1 demonstrated by a Ki of 0.55 nM, AM8936 is effective in vivo. This compound is instrumental in research related to central nervous system disorders, metabolic diseases, pain management, and glaucoma. -
Cannabinoid Receptor Antagonist
Hemopressin (rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, with its origins traced to rat brain homogenates. This compound serves as a selective inverse agonist of CB1 cannabinoid receptors, demonstrating oral bioactivity. Hemopressin (rat) TFA exhibits significant antinociceptive effects in models of inflammatory pain, making it a valuable tool for research in pain modulation and cannabinoid receptor biology. -
CB1 Antagonist
ABD459 is a selective CB1 receptor antagonist that plays a crucial role in modulating food intake and sleep-wake cycles. It effectively displaces the CB1 agonist CP99540 with a Ki value of 8.6 nM and antagonizes CP55940-induced GTPγS binding, exhibiting a KB value of 7.7 nM. This compound may influence endogenous cannabinoid release via cholinergic activity and is relevant for research focused on neurological disorders and attentional processes. -
CB1 Receptor Antagonist
CB1 Antagonist 5 is a selective antagonist of the cannabinoid receptor type 1 (CB1), exhibiting a Ki value of 243 nM alongside an EC50 of 195 nM. This compound is valuable for research applications targeting the endocannabinoid system and may assist in studies related to pain modulation, appetite regulation, and neuroprotection. Its specificity for the CB1 receptor makes it an essential tool for exploring the physiological roles and therapeutic potentials of cannabinoid signaling. -
Cannabinoid
(-)-11-Hydroxy-Δ8-tetrahydrocannabivarin is a synthetic cannabinoid that primarily targets cannabinoid receptors. It exhibits biological activities related to modulation of the endocannabinoid system, making it suitable for research into therapeutic applications in pain relief, appetite regulation, and neurological disorders. This compound is valuable for studies focused on the pharmacological effects of cannabinoids and their potential medicinal uses. -
Phytocannabinoid Derivative
exo-Tetrahydrocannabivarin methyl ether is a phytocannabinoid derivative that interacts with cannabinoid receptors in the endocannabinoid system. This compound exhibits potential analgesic and anti-inflammatory properties, making it a valuable tool for research in pain management and inflammation studies. Its structural similarity to other phytocannabinoids allows for comparative studies on cannabinoid activity and therapeutic applications. -
Phytocannabinoid Derivative
10(S)-Hydroxy-9(R)-hexahydrocannabinol is a phytocannabinoid derivative known for its interactions with cannabinoid receptors. This compound exhibits biological activity that may influence neuroprotective and analgesic pathways. It is useful in research studies focused on the endocannabinoid system, offering insights into the pharmacological properties of cannabinoids in therapeutic contexts. -
Phytocannabinoid Derivative
Δ8-THC-ethyl (Ethyl-Δ8-Tetrahydrocannabinol) is a phytocannabinoid derivative that exerts its effects primarily through cannabinoid receptors in the endocannabinoid system. This compound is of significant interest for research into its potential therapeutic effects, including anxiolytic and analgesic properties. It is utilized in studies investigating the biological mechanisms of cannabinoids and their implications in various neurological and physiological processes. -
Cannabinoid Derivative
Cannabigerophorol (CBGP) is a cannabinoid derivative that acts on the cannabinoid receptors in the endocannabinoid system. This compound exhibits notable biological activity, including potential analgesic and anti-inflammatory effects. Researchers utilize CBGP to explore its therapeutic applications in pain management, neuroprotection, and other conditions influenced by the endocannabinoid system. -
Ether Analogs of Cannabinoids
8β-Hydroxy-exo-THC is a cannabinoid ether analog that primarily targets cannabinoid receptors. This compound exhibits a modest receptor affinity, with an IC50 value of 1.2 μM. It is utilized in research to explore the pharmacological properties of cannabinoid derivatives and their potential therapeutic applications. -
Cannabinoid
ADB-BINACA is a synthetic cannabinoid that targets the cannabinoid receptors in the endocannabinoid system. It exhibits potent agonistic activity at both CB1 and CB2 receptors, making it useful in the exploration of cannabinoid signaling pathways. This compound is often utilized in pharmacological studies and research related to cannabinoid-based therapies and neurological disorders. -
Phytocannabinoid Derivative
Δ8-THCBA-A is a phytocannabinoid derivative that functions as a selective modulator of cannabinoid receptors. It exhibits notable biological activity by influencing cannabinoid signaling pathways, making it valuable for research in the fields of neuropharmacology and cannabinoid pharmacology. Its unique structural properties and receptor interactions facilitate the exploration of therapeutic applications related to cannabinoid-based treatments. -
Cannabinoid Receptor
Arachidonoyl-N,N-dimethyl amide targets cannabinoid receptors with reduced binding affinity for the human central cannabinoid (CB1) receptor (Ki >1 μM). This analog of anandamide demonstrates significant biological activity by completely inhibiting rat glial gap junction communication at a concentration of 50 μM. Its unique properties make it a valuable tool for investigating cannabinoid signaling and understanding the role of endocannabinoids in neurological functions. -
Cannabinoid Receptor
6α-Oxycodol N-oxide is an opioid derivative that primarily targets the cannabinoid receptor. As a metabolite of Oxycodone, it exhibits potential biological activity relevant to pain modulation and cannabinoid signaling pathways. This compound is useful for research applications focused on opioid-cannabinoid interactions and the investigation of analgesic mechanisms. -
GPR55 Fluorescent Ligand
Tocrifluor 1117 is a selective fluorescent ligand targeting the GPR55 receptor. This compound serves as a valuable tool in research for visualizing the cellular distribution of cannabinoid receptors, including GPR55, in live tissues. With excitation and emission maxima at 543 nm and 590 nm, respectively, Tocrifluor 1117 enhances the understanding of cannabinoid receptor localization and function in various biological contexts. -
Phytocannabinoid Derivative
Hexocannabitriol is a phytocannabinoid derivative that interacts with the endocannabinoid system, primarily targeting cannabinoid receptors. Its structural similarity to other phytocannabinoids suggests potential for modulating various physiological processes, including pain relief and anti-inflammatory effects. This compound is suitable for research applications investigating cannabinoid receptor signaling pathways and the therapeutic effects of cannabinoids in various biological models. -
Cannabinoid Receptor
Cannabinol methyl ether primarily targets the cannabinoid receptors in the body. This compound exhibits potential biological activity related to modulation of cannabinoid signaling pathways. Its applications in research include the study of cannabis-derived compounds in therapeutic contexts and the exploration of their effects on various physiological processes. -
Cannabinoid Receptor
Cannabigerovarin is a phytocannabinoid that primarily targets cannabinoid receptors. It exhibits significant biological activity in modulating the endocannabinoid system, making it valuable for research in cannabinoid pharmacology and its potential therapeutic applications. This compound is suitable for various scientific investigations, including studies on the effects of cannabinoids in both preclinical and forensic contexts. -
Cannabinoid
PTI-1 is a synthetic cannabinoid that targets cannabinoid receptors, exhibiting efficacy in modulating the endocannabinoid system. It is primarily used in research to explore the therapeutic potential of cannabinoids in various neurological and inflammatory conditions. The compound's ability to mimic endogenous cannabinoids makes it a valuable tool for studying receptor activation and downstream signaling pathways. -
Analog of Phytocannabinoids
Δ8-THCB (∆8-Tetrahydrocannabutol) is an analog of phytocannabinoids, specifically related to Δ8-tetrahydrocannabinol. This compound exhibits significant activity at cannabinoid receptors, which contributes to its potential therapeutic benefits. Δ8-THCB is primarily utilized in research focused on cannabinoid signaling pathways and pharmacological studies related to the endocannabinoid system. -
Phytocannabinoid Derivative
11-Nor-9(S)-carboxy-hexahydrocannabinol is a phytocannabinoid derivative that displays significant interaction with the endocannabinoid system, primarily through modulation of cannabinoid receptors. This compound exhibits potential anti-inflammatory and analgesic effects, making it valuable for research in pain management and neuroprotection. Its structural similarity to known phytocannabinoids allows for comparative studies in cannabinoid pharmacology and therapeutic applications. -
Endocannabinoid
Tricosanoyl ethanolamide is an endocannabinoid that derives from ethanolamine and tricosanoic acid, featuring a unique 23-carbon chain. This compound engages with endocannabinoid receptors and plays a crucial role in modulating various physiological processes. Tricosanoyl ethanolamide is valuable for research into diseases linked to the endocannabinoid system, providing insights into its potential therapeutic applications. -
Phytocannabinoid Derivative
Cannabinol acetate, a phytocannabinoid derivative, is structurally related to recognized phytocannabinoids. This compound has been studied for its potential pharmacological effects, particularly in modulating cannabinoid receptors. Its research applications include investigations into neuroprotection, analgesia, and potential therapeutic benefits in various ailments associated with the endocannabinoid system. -
Cannabinoid Receptor
Cannabinol ethyl (CBN-C2) acts as a cannabinoid receptor agonist, engaging with the endocannabinoid system to modulate various physiological processes. It exhibits notable anti-inflammatory and analgesic properties, making it valuable for research into pain management and neurological disorders. This compound provides a useful tool for studying cannabinoid receptor pathways and their implications in health and disease. -
Phytocannabinoid Derivative
8(S)-Hydroxy-9(S)-hexahydrocannabinol is a phytocannabinoid derivative that exhibits structural similarities to other known cannabinoids. This compound is of interest for its potential biological activities, including modulation of cannabinoid receptors and influence on signaling pathways associated with pain and inflammation. It is primarily utilized in research focusing on the pharmacological effects of cannabinoids, offering insights into their therapeutic applications for various health conditions. -
Phytocannabinoid Derivative
exo-THCP (exo-Tetrahydrocannabiphorol) is a phytocannabinoid derivative that exhibits affinity for cannabinoid receptors. This compound is recognized for its potential to influence various biological processes and has been implicated in research related to pain relief, inflammation, and neuroprotection. Its structural similarity to established phytocannabinoids enables exploration of its therapeutic potential and elucidation of cannabinoid signaling pathways. -
Phytocannabinoid Metabolite
(±)-6',7'-Dihydroxy cannabichromene is a phytocannabinoid metabolite that functions primarily as a cannabinoid receptor agonist. This compound exhibits significant biological activity by modulating cannabinoid receptor signaling pathways, making it a valuable tool for research in cannabinoid pharmacology and potential therapeutic applications. Its role in the study of the endocannabinoid system highlights its relevance in investigating the effects of cannabinoids on various physiological processes. -
Phytocannabinoid Derivative
Δ9-THCBA-A is a phytocannabinoid derivative that primarily targets the cannabinoid receptors within the endocannabinoid system. This compound exhibits significant biological activity, contributing to the modulation of various physiological processes. Its research applications include studies on cannabinoid receptor signaling, potential analgesic effects, and anti-inflammatory mechanisms, making it a valuable tool for exploring the therapeutic benefits of cannabinoids. -
Phytocannabinoid Derivative
5'-Hydroxy-9(S)-hexahydrocannabinol is a phytocannabinoid derivative that exhibits structural similarities to established cannabinoids. This compound demonstrates significant biological activity with potential applications in cannabinoid receptor research and studies investigating the therapeutic effects of cannabis-derived substances. It serves as a valuable tool for exploring the pharmacological properties and metabolic pathways of cannabinoids in various biological systems. -
Anandamide Analog
5Z,8Z,11Z,14Z-Eicosatetraenoic acid, 3-thienylmethyl ester is an analog of anandamide, a naturally occurring endocannabinoid that interacts with cannabinoid receptors. This compound exhibits significant biological activity, potentially influencing cannabinoid receptor signaling pathways. It is a valuable tool for research applications exploring the endocannabinoid system and its effects on physiological processes. -
Cannabinoid Derivative
MEP-FUBICA is a synthetic cannabinoid derivative that primarily targets the cannabinoid receptors in the endocannabinoid system. It exhibits distinct biological activities, including modulation of receptor signaling pathways associated with pain, inflammation, and neuroprotection. MEP-FUBICA is utilized in research applications focused on the pharmacological effects of cannabinoids and their potential therapeutic benefits in various medical conditions. -
Cannabinoid Receptor
Cannabifuran is a cannabinoid receptor modulator that exhibits structural similarity to established phytocannabinoids. This compound demonstrates potential biological activity in the modulation of endocannabinoid signaling pathways. It can be utilized in research applications exploring the therapeutic effects of cannabinoids on various physiological processes, including pain management, inflammation, and neurological disorders. -
Cannabinoid Receptor
1-(1-Methyl-1H-indol-3-yl)-2-(1-naphthalenyl)ethanone functions as a potent agonist at cannabinoid receptors, providing insight into cannabinoid signaling pathways. This compound exhibits significant biological activity, making it valuable for research applications in the exploration of endocannabinoid system interactions, pharmacology, and potential therapeutic effects. Its structural resemblance to known synthetic cannabinoids adds to its relevance in studies of cannabinoid receptor modulation. -
CB1 Receptor Antagonist
PF-514273 is a highly selective antagonist of the cannabinoid-1 receptor (CB1), exhibiting an IC50 of 1 nM. This compound demonstrates notable efficacy in reducing food intake in murine models, making it a valuable tool for obesity research. PF-514273 can be utilized to explore the role of CB1 signaling in appetite regulation and related metabolic disorders. -
Cannabinoid Derivative
ADB-BICA is a synthetic cannabinoid derivative that acts primarily on the cannabinoid receptors in the endocannabinoid system. It exhibits key biological activity by modulating receptor signaling, which is essential for research in areas such as neuropharmacology and therapeutic potential of cannabinoids. This compound is utilized to study the effects of cannabinoids on various physiological processes and is valuable in the exploration of cannabinoid-based treatments. -
Cannabinoid-like Analog
BZO-CHMOXIZID is a cannabinoid-like analog that primarily targets cannabinoid receptors. This compound modulates the endocannabinoid system, demonstrating potential anxiolytic and analgesic effects. BZO-CHMOXIZID can be utilized in research applications focusing on neuropharmacology, pain management, and therapeutic mechanisms of cannabinoids. -
Cannabinoid Derivative
Azidoindolene 1 is a cannabinoid derivative that functions as an analog in various biological studies. It exhibits potential activity at cannabinoid receptors, making it relevant for research into endocannabinoid signaling pathways. This compound is useful for investigations into the physiological effects of cannabinoids and their therapeutic applications. -
Anandamide Analog
Arachidonoyl 2'-fluoroethylamide is an anandamide analog that specifically targets cannabinoid receptors. This compound exhibits significant biological activity, influencing endocannabinoid signaling pathways, and has potential applications in research focused on intraocular hypertension. Studies may explore its effects on ocular pressure regulation and its therapeutic implications for related conditions. -
Phytocannabinoid Metabolite
(±)-6',7'-Epoxy cannabichromene is a phytocannabinoid metabolite that selectively interacts with various cannabinoid receptors in the endocannabinoid system. This compound showcases notable biological activity, including modulation of pain and inflammation pathways. Research applications include exploring its potential therapeutic effects in neurological disorders and understanding the pharmacological properties of cannabinoid derivatives.
